Adagene (ADAG) Shares Outstanding (2019 - 2026)
Adagene (ADAG) posted quarterly Shares Outstanding (Entity) of $59.0 million for Q4 2025, up 4.83% year-over-year from $56.3 million in Q4 2024, and little changed quarter-over-quarter from $58.9 million in Q2 2025.
Analysis
Adagene (ADAG) Shares Outstanding (2019 - 2026) Analysis & Trends
Adagene (ADAG) has reported Shares Outstanding (Entity) for 7 consecutive years, with $59.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 4.83% year-over-year to $59.0 million; the TTM figure through Dec 2025 stood at $59.0 million (up 4.83% YoY), while the FY2025 annual figure was $59.0 million, up 4.83% from the prior year.
- Shares Outstanding (Entity) steadied at $59.0 million in Q4 2025 per ADAG's latest filing, from $58.9 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $59.0 million in Q4 2025 and bottomed at $36.4 million in Q2 2021.
- Historically, Shares Outstanding (Entity) has averaged $51.3 million across 5 years, with a median of $54.7 million in 2023.
- Annual changes were most pronounced in 2021 — Shares Outstanding (Entity) surged 213.67% — and 2023, when it gained 1.11%.
- Adagene's Shares Outstanding (Entity) stood at $40.0 million in 2021, then jumped by 35.25% to $54.1 million in 2022, then rose by 1.11% to $54.7 million in 2023, then advanced by 2.83% to $56.3 million in 2024, then advanced by 4.83% to $59.0 million in 2025.
- Business Quant data shows ADAG's Shares Outstanding (Entity) at $59.0 million in Q4 2025, $58.9 million in Q2 2025, and $56.3 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 61.30 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 398.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 210.89 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 111.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 445.06 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Adagene | 214.19 Mn | 214.19 Mn | - | 59.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 59.01 Mn |
| Dec 31, 2025 | 59.01 Mn |
| Jun 30, 2025 | 56.29 Mn |
| Dec 31, 2024 | 56.29 Mn |
| Jun 30, 2024 | 54.74 Mn |
| Dec 31, 2023 | 54.74 Mn |
| Jun 30, 2023 | 54.14 Mn |
| Dec 31, 2022 | 54.14 Mn |
| Jun 30, 2022 | 50.03 Mn |
| Dec 31, 2021 | 50.03 Mn |
| Jun 30, 2021 | 15.95 Mn |
| Dec 31, 2020 | 15.95 Mn |
| Dec 31, 2019 | 15.18 Mn |